A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.
Video content above is prompted by the following question:
a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?
b. How would the introduction of an oral therapy for CSU influence your treatment decisions?
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
June 20th 2025Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.
Read More
Topical Ruxolitinib Emerges as Promising Therapy for Diverse Inflammatory Skin Conditions
June 17th 2025Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic conditions.
Read More